PRednisone Plus EVerolimus in Patients With Metastatic Renal Cell Cancer After Failure of VEGFR -TKI
Status:
Terminated
Trial end date:
2017-09-01
Target enrollment:
Participant gender:
Summary
This is a multicenter prospective study that includes all patients with metastatic Renal Cell
Cancer (RCC) pre- treated with VEGFR TKI in eight Italian cancer centers.
Everolimus is formulated as tablets of 5-10 mg strength, blister-packed under aluminium foil
in units of 10 tablets. Prednisone will be dispensed to patients at the dose of 5 mg twice
daily (BID). Everolimus at dose of 10 mg (one 10 mg tablet or two 5 mg tablets). Both drugs
will be self-administered orally, continuously from Day 1 (Visit 2) until progression of
disease, unacceptable toxicity, death or discontinuation for any other reason.
A treatment cycle consists of 28 days.
Phase:
Phase 2
Details
Lead Sponsor:
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori